OBJECTIVES: Anxiety disorders represent the most common psychiatric illness in the US Pharmacotherapy is the most common approach to treat anxiety disorders. Our objective is to determine the extent to which patients with anxiety disorder seek pharmacological treatment and to examine factors that are associated with the pharmacological treatment utilization. METHODS: We evaluated Medical Expenditures Panel Survey (MEPS) data (data pooled for survey calendar years 2005- 2009). Adult MEPS respondents (age+17), identified as having anxiety disorder condition (n = 3412) were included in the study. Andersen behavioral model of health services utilization was used as the conceptual framework for the study. Dependent variables were defined as utilization of anti-anxiety medications (model A) and number of prescriptions for anxiety disorders (model B). Independent variables, i.e. predisposing, enabling and need variables, were defined for each model based on current literature and availability in MEPS. Logistic regression (model A) and Poisson regression (model B) analyses were conducted to find the predictors of medication utilization as well as the number of prescriptions. RESULTS: Sixty-one percent of adults with anxiety disorder take anti-anxiety medication (95% CI: 59%, 63%). For model A, significant variables were race (Native Hawaiian/Pacific Islander versus white, OR<0.001, p<0.001), education (no education versus elementary school, OR= 0.295, p=0.039), prescription drug insurance coverage (no coverage versus coverage for at least one round in year, OR= 0.768, p= 0.005), insurance coverage (private insurance versus public insurance, OR= 0.749, p= 0.034), having irritable bowel syndrome (IBS) (OR=2.951, p=0.016), and mood disorder (OR=2.194, p<0.0001). For model B, significant variables were cost index (beta =-0.391, p<0.0001), number of comorbidities (beta=0.163, p<0.0001) and age (beta=-0.174, p= 0.043). CONCLUSIONS: Utilization rate of anti-anxiety medications among adult patients with anxiety disorder is high. Demographic variables are less likely to affect this utilization, while enabling and clinical need variables are highly influential.
Shirneshan, E., Hong, S. H., & Brown, L. L. (2012). PMH64 Anti-Anxiety Medication Utilization among Patients with Anxiety Disorder: Analysis of Medical Expenditure Panel Survey. Value in Health, 15(4), A93. https://doi.org/10.1016/j.jval.2012.03.509